argenx SE American Depositary Shares (ARGX)

About ARGX

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for t…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

1,863

Website

www.argenx.com/

Fundamentals

1-day range

$1,019$1,053

Market cap

$51.56B

P/E (trailing)

22.19

P/E (forward)

26.08

EPS (trailing)

$37.84

Dividend yield

—

Beta

1.49

Avg. volume

339.9K

Forecasts

23 analyst ratings

argenx SE American Depositary Shares Competitors

Chosen by industry and closest market cap.

• ARGX

  argenx SE American Depositary Shares

  $1,025

  ▼ 3.22%
  Market cap $51.56BP/E 22.19
  $568.4$913
• RVMD

  Revolution Medicines Inc. Common Stock

  $207.89

  ▼ 6.00%
  Market cap $38.79BP/E —
  $35.64$224.31
• BNTX

  BioNTech SE American Depositary Share

  $102.04

  ▼ 8.40%
  Market cap $23.18BP/E —
  $79.52$124
• MRNA

  Moderna Inc. Common Stock

  $137.93

  ▼ 3.39%
  Market cap $21.88BP/E —
  $22.28$176.66
• HALO

  Halozyme Therapeutics Inc. Common Stock

  $105.33

  ▼ 1.49%
  Market cap $9.76BP/E 27.63
  $61.23$109.66
• QGEN

  Qiagen N.V. Common Shares

  $43.12

  ▼ 1.43%
  Market cap $8.72BP/E 22.14
  $32.53$57.82
• KYMR

  Kymera Therapeutics Inc. Common Stock

  $118.08

  ▼ 1.79%
  Market cap $8.25BP/E —
  $39.84$130.05

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• UBS Upgrades argenx to Buy, Raises Price Target to $1400
  benzinga · 8/26/2026
• UBS Upgrades argenx to Buy, Raises Price Target to $1400
  Benzinga · 8/26/2026
• Wells Fargo Maintains Overweight on argenx, Raises Price Target to $1415
  Benzinga · 8/26/2026
• argenx SE (ARGX) Discusses Positive Phase 3 ALKIVIA Trial Results for VYVGART Hytrulo in Autoimmune Myositis - Slideshow
  SeekingAlpha · 8/20/2026
• Truist Securities Maintains Buy on argenx, Raises Price Target to $1095
  Benzinga · 8/18/2026
• argenx SE (ARGX) Discusses Positive Phase 3 ALKIVIA Trial Results for VYVGART Hytrulo in Autoimmune Myositis Transcript
  SeekingAlpha · 8/18/2026
• RBC Capital Maintains Outperform on argenx, Raises Price Target to $1100
  Benzinga · 8/18/2026
• Snowflake To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday
  Benzinga · 8/18/2026
• These Analysts Boost Their Forecasts On Argenx
  Benzinga · 8/18/2026

Institutional Ownership

March 31, 2026

Total shares held

29.26M

Total value held

$18.60B

Institutional holders

474